Latest news for Orexo (OTC:ORXOY) Stock

Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Biotech

News

Penny Stocks

Health Care

General

INVVY

IZQVF

ORXOF

ORXOY

The FDA warned patients and prescribers about the risk of potential dental problems arising from the us

Using Opioid Addiction Drug Buprenorphine May Cause Dental Issues, FDA Flags

Movers & Shakers

Small Cap

Events

Global

Markets

Trading Ideas

ETFs

BNIGF

EMMA

LXRP

MBRX

NRIFF

RDHL

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

In addition to causing chaos in markets and economies around the world, the spread of the COVID-19 coronavirus has put the biotechnology and health care industries under the microscope.

With The World In The Midst Of A Pandemic, Attention Turns To Life Sciences

Orexo AB

TD Securities analyst Craig Hutchison maintains MAG Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#TSX">MAG</a>) with a Buy and raises the price target from C$26 to C$27.

Price Target

Analyst Ratings

TSX:MAG

TD Securities Maintains Buy on MAG Silver, Raises Price Target to C$27

TD Securities analyst Daniel Chan maintains CGI (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GIB#TSX">GIB</a>) with a Buy and raises the price target from C$180 to C$190.

TSX:GIB

TSX:GIB/A

TD Securities Maintains Buy on CGI, Raises Price Target to C$190

Citigroup analyst Ronald Josey maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $753 to $780.

Citigroup Maintains Buy on Meta Platforms, Raises Price Target to $780

Citigroup analyst Jon Tower maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Neutral and raises the price target from $166 to $185.

Citigroup Maintains Neutral on Brinker International, Raises Price Target to $185

Citigroup analyst Scott Gruber maintains Seadrill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) with a Buy and lowers the price target from $50 to $46.

SDRL

Citigroup Maintains Buy on Seadrill, Lowers Price Target to $46

American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) has outperformed the market over the past 5 years by 6.37% on an annualized basis producing an average annual return of 19.32%. Currently, American Express has a market capitalization of $223.90 billion. 
Buying $100 In AXP: If an investor had bought $100 of AXP stock 5 years ago, it would be worth $243.47 today based on a price of $318.95 for AXP at the time of writing.
<h3>American Express's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738278015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning American Express Stock In The Last 5 Years

Citigroup analyst Scott Gruber maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Neutral and raises the price target from $47 to $48.

Citigroup Maintains Neutral on Valaris, Raises Price Target to $48

Citigroup analyst Asiya Merchant maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and lowers the price target from $82 to $80.

Citigroup Maintains Buy on Western Digital, Lowers Price Target to $80

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $285 to $265.

Citigroup Maintains Buy on Danaher, Lowers Price Target to $265

Citigroup analyst George Choi maintains Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Buy and raises the price target from $64.5 to $67.

Citigroup Maintains Buy on Las Vegas Sands, Raises Price Target to $67

Maxim Group analyst Jason McCarthy maintains Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) with a Buy and raises the price target from $8 to $12.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Maxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

Earnings

HFBL

CORRECTION: Home Federal Bancorp Q2 EPS $0.33, Flat YoY

Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) has outperformed the market over the past 5 years by 18.24% on an annualized basis producing an average annual return of 31.2%. Currently, Cheniere Energy has a market capitalization of $51.65 billion. 
Buying $1000 In LNG: If an investor had bought $1000 of LNG stock 5 years ago, it would be worth $3,918.96 today based on a price of $230.20 for LNG at the time of writing.
<h3>Cheniere Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738277138_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Cheniere Energy 5 Years Ago Would Be Worth This Much Today

Shares of Common Stock are expected to begin trading on the New York Stock Exchange under the ticker symbol "INR." The offering is expected to close on February 3, 2025, subject to customary closing conditions.

IPOs

Infinity Natural Resources Prices Public Offering Of 13.25M Shares Of Class A Common Stock At $20.00 Per Share

Maxim Group analyst Allen Klee initiates coverage on Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) with a Buy rating and announces Price Target of $5.

Initiation

ORKT

Maxim Group Initiates Coverage On Orangekloud Technology with Buy Rating, Announces Price Target of $5

Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) shares are falling in extended trading Thursday after the company <a href="https://www.benzinga.com/pressreleases/25/01/b43355741/walgreens-boots-alliance-suspends-quarterly-dividend-as-company-continues-disciplined-execution-ag">suspended its quarterly dividend</a>.
What Happened: After the market close on Thursday, Walgreens announced its board is suspending its cash dividend as management continues to evaluate its capital allocation policy as part of a longer-term turnaround strategy.
The suspended dividend is expected to help strengthen the company&#8217;s balance sheet by reducing debt over time and improving free cash flow.
&#8220;The company&#8217;s cash needs over the next several years, including with respect to litigation and debt refinancing, were important considerations as part of the decision to suspend the dividend,&#8221; the company said. 
&#8220;WBA leadership remains focused on successfully executing against its strategic priorities and maintaining financial discipline, which it believes will deliver sustained value creation over the long term.&#8221;
<h1 class="wp-block-heading">How To Buy WBA Stock</h1>
By now you're likely curious about how to participate in the market for Walgreens — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share. 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading — either way it allows you to profit off of the share price decline.
WBA Price Action: <a href="http://benzinga.com/quote/wba">Walgreens shares</a> were down 7.77% after-hours, trading at $10.52 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever">Apple Q1 Earnings: Revenue Beat, EPS Beat, iPhone Sales Slip, Installed Base Climbs To All-Time High — &#8216;Our Best Quarter Ever&#8217;</a></li>
</ul>
Photo: Courtesy of Walgreens Boots Alliance.

Dividends

After-Hours Center

Walgreens Boots Alliance Shares Slide As Board Suspends Dividend

For the quarter ended December 31, 2024, the company reported a net loss of $2.0 million, or $0.03 per diluted common share, compared to net income of $0.9 million, or $0.01 per diluted common share, for the quarter ended September 30, 2024, and a net loss of $5.8 million for the fourth quarter of 2023.&nbsp;

BRBS

Blue Ridge Bankshares Q4 EPS $(0.03), Says Regulatory Remediation Efforts On Track

Lake Street analyst Eric Martinuzzi maintains Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) with a Hold and raises the price target from $15 to $16.

EXTR

Lake Street Maintains Hold on Extreme Networks, Raises Price Target to $16

Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) reported its third-quarter financial results after Thursday's closing bell. Here's a look at the<a href="https://www.benzinga.com/pressreleases/25/01/b43352747/boot-barn-holdings-inc-announces-third-quarter-fiscal-year-2025-financial-results"> details from the report.&nbsp;</a>
The Details:&nbsp;Boot Barn reported earnings of $2.43 per share, beating the $2.29 estimate. Quarterly revenue came in at $608.17 million, beating the $607.01 million estimate.
Same-store sales increased 8.6% compared to the prior-year period, comprised of an increase of 8.2% in retail store same-store sales and an increase of 11.1% in e-commerce same-store sales. The company opened 13 new stores, bringing its total store count to 438 as of the quarter end.
Read Next: <a href="https://www.benzinga.com/general/travel/25/01/43343648/all-60-passengers-4-crew-members-onboard-american-airlines-jet-feared-dead-after-midair-collision-official-says">64 Killed In American Airlines Midair Collision Near D.C., Worst US Air Disaster Since 2001&nbsp;</a>
&#8220;I want to thank the entire Boot Barn team for their excellent execution and dedication during a busy holiday season, which resulted in strong third-quarter results and earnings per diluted share above the high end of our guidance range. The strength we saw in the business was once again driven by broad-based growth across all major merchandise categories, channels and geographies, resulting in a consolidated same-store sales increase of 8.6%,&#8221; said John Hazen, Interim CEO.
&#8220;We also grew total sales 16.9% compared to the prior-year period, driven in part by the 13 new stores we opened in the third quarter and the 39 new stores we have opened year-to-date through our third fiscal quarter,&#8221; Hazen added. 
Outlook:&nbsp;Boot Barn raised its fiscal 2025 GAAP EPS guidance from a range of&nbsp;$5.30 to $5.60 to a range of $5.81 to $5.90, versus the&nbsp;$5.76&nbsp;estimate, and raised its fiscal 2025 sales guidance from a range of $1.87 billion to $1.91 billion to&nbsp;a range of $1.91 billion to $1.92 billion, versus the $1.91 billion estimate. 
BOOT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Boot Barn Holdings shares are down 6.60% after-hours at $163 on Thursday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details">Microsoft Shares Slide After Q2 Results, Cloud Revenue Misses Expectations: Details</a>&nbsp;</li>
</ul>
Photo: Courtesy of Boot Barn Holdings, Inc.

Movers

BOOT

Boot Barn Stock Falls After Q3 Report: What To Know

Loop Capital analyst Alton Stump maintains Silgan Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLGN#NYSE">SLGN</a>) with a Buy and raises the price target from $70 to $75.

SLGN

Loop Capital Maintains Buy on Silgan Hldgs, Raises Price Target to $75

Press Releases

Orexo: invitation to presentation of the Q2 2024 Interim Report

Orexo AB's sustainability work ranked among top 5% by EcoVadis

Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose

Orexo Q2 2024 Interim Report

Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024

Orexo's Nomination Committee for the Annual General Meeting 2025

Orexo Interim Report Q3 2024

Orexo initiates new study of OX640 in participants with allergic rhinitis

Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology

Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis

Orexo

The&nbsp;<a class="editor-rtfLink" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-risks-dental-problems-associated-buprenorphine-medicines-dissolved-mouth-treat" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FDA warned patients and prescribers</a>&nbsp;about the risk of potential dental problems arising from the use of buprenorphine medicines to treat opioid addiction and pain.

<ul>
	<li>The agency said the opioid addiction treatment had been reported to cause tooth decay, infection, and, in some cases, total tooth loss in patients with no history of dental issues.</li>
	<li>The buprenorphine medicines that are associated with dental problems are tablets dissolved under the tongue and films placed against the inside of the cheek.</li>
	<li>The FDA approved buprenorphine as a tablet in 2002 and as a film in 2015.</li>
	<li>It said patients might lessen their risk by taking preventative measures.</li>
	<li>After the product is completely dissolved, patients should take a large sip of water, swish it gently around their teeth and gums, and swallow, waiting for at least one hour before brushing their teeth after using the product to avoid damage to the teeth.</li>
	<li>The regulator&#39;s approved buprenorphine products include&nbsp;Orexo AB&#39;s&nbsp;(OTC:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/orxof#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">ORXOF</a>) Zubsolv and&nbsp;Indivior Plc&#39;s&nbsp;(OTC:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/invvy#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">INVVY</a>) Suboclade.</li>
</ul>

The following post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga.

In addition to causing chaos in markets and economies around the world, the spread of the COVID-19 coronavirus has put the biotechnology and health care industries under the microscope.

Suddenly, hundreds of such companies are redirecting resources in an effort to find a vaccine or treatment that could potentially halt the virus&rsquo; spread. This has made the biotech space one of the few hot spots in a historically bad month for stocks.

The shelter-in-place orders in the U.S. and other countries have also made it difficult for many of these companies to communicate directly with investors. This is especially challenging for biotech companies, which are often more communicative with investors than companies in other industries. Expensive drug trial and capital raising cycles, make constant communication with investors essential, according to John Viglotti, senior vice president of corporate services and investor access at OTC Markets.

&ldquo;They are faced with a constant need to raise capital to fund clinical trials, and these clinical trials are not stopping,&rdquo; he said. &ldquo;The life science business is certainly continuing.&rdquo;

In an effort to bridge that gap between investors hungry for information and companies trying to reach them, OTC Markets is hosting the first <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">Virtual Life Science Investor Forum</a> on March 26. The online-only conference will consist of investor presentations from seven companies in five countries. Some will be giving updates on their COVID-19 treatments.

&ldquo;Certainly with what&rsquo;s going on with the coronavirus pandemic, it just makes it that much more relevant,&rdquo; said Jason Paltrowitz, executive vice president of corporate services at OTC Markets. &ldquo;The public at large is certainly interested in COVID-19, but from an investor perspective there are great opportunities.&rdquo;

According to Viglotti, over 200 life sciences companies have previously participated in virtual investor conferences, making it one of the most popular sectors to participate in the conference series.

&ldquo;It was really done with the realization that there are so many pre-revenue, early stage private life science companies that are just starved for attention,&rdquo; Paltrowitz said of this week&rsquo;s conference. &ldquo;And we thought being able to host a series of virtual conferences would help.&rdquo;

Below is the schedule for the conference. Each presentation is followed by a virtual Q&amp;A session with attendees and is available on demand.

To learn more about attending Thursday&rsquo;s conference, <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">click here</a>.

9:30 AM ET RedHill Biopharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) 
Speaker: Guy Goldberg, Chief Business Officer 
About: RedHill is a specialty biopharmaceutical company focused on gastrointestinal diseases. RedHill has commercial operations in the U.S., with a sales force promoting several gastrointestinal drugs across the U.S., including RedHill&rsquo;s recently FDA approved drug, Talicia&reg;. RedHill also has a robust development pipeline with several late-stage development programs which have successfully completed Phase 3 studies.

10:00 AM ET Nuvo Pharmaceuticals Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NRIFF#OTCQX">NRIFF</a>) 
Speakers: Jesse Ledger, President &amp; Chief Executive Officer, and Kelly Demerino, Interim Chief Financial Officer 
About: Nuvo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company&#39;s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.

10:30 AM ET Orexo AB (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ORXOY#OTCQX">ORXOY</a>) 
Speaker: Nikolaj S&oslash;rensen, President &amp; CEO 
About: Orexo develops improved pharmaceuti&shy;cals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv&reg; for treatment of opioid use disor&shy;der.

11:00 AM ET Emmaus Life Sciences, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/EMMA#OTCQB">EMMA</a>) 
Speakers: Dr. Yutaka Niihara, Chairman and Chief Executive Officer, and Jay Sherwood 
Chief Financial Officer

About: Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. Its FDA-approved Endari&reg; (prescription grade L-glutamine oral powder) is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

11:30 AM ET Moleculin Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) 
Speaker: Walter Klemp, Founder, President, CEO &amp; Chairman 
About: Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company&#39;s clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition.

12:00 PM ET Lexaria Bioscience Corp. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/LXRP#OTCQX">LXRP</a>) 
Speaker: Chris Bunka, CEO 
About: Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH&trade; drug delivery technology changes the way API&#39;s enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

12:30 PM ET Beroni Group Ltd. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/BNIGF#OTCQX">BNIGF</a>) 
Speakers: Jacky Zhang, Chairman and CEO, and Peter Wong, Group CFO 
About: Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) with business presence in Australia, China, Japan and the USA. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection &amp; diagnosis of infectious diseases.

To learn more about attending Thursday&rsquo;s conference, <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">click here</a>.

Photo by&nbsp;<a href="https://unsplash.com/@thisisengineering?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">ThisisEngineering RAEng</a>&nbsp;on&nbsp;<a href="https://unsplash.com/s/photos/laboratory?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Comments

Orexo

News

Latest news for Orexo (OTC:ORXOY) Stock

Thursday, January 13, 2022

Wednesday, March 25, 2020

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga